Combined tumour necrosis factor- and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF- therapy and explain controversies of studies based on a single polymorphism

Abstract excerpt

Sir, Tumour necrosis factor-α (TNF-α) blocker therapies are widely used in the treatment of chronic inflammatory diseases. However, patients show large heterogeneity in their response to anti-TNF-α therapy. The genotypic background of TNF-α and TNF receptor (TNFR) genes could account for patients’ resistance to TNF-α blockers [1, 2]. HLA-DR haplotypes have been related with rheumatoid arthritis (RA)...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Monoclonal and Polyclonal Antibodies Research
• Share to Rheumatoid Arthritis Research and Therapies